NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange

Executive Summary

• NervGen Pharma Corp. will voluntarily delist its common shares from the TSX Venture Exchange (TSXV) effective March 16, 2026, remaining listed on Nasdaq under “NGEN”.
• The delisting was approved by the Board to eliminate duplicate exchange fees and reduce legal, accounting, and regulatory complexity, allowing greater focus on clinical execution.
• The company terminated its previously announced at‑the‑market (ATM) equity program, having issued 245 common shares from Jan 1 – Mar 12 2026 at a weighted‑average price of $6.20, generating net proceeds of $1,489.

Key Details

• Delisting: Voluntary removal of NGEN’s TSXV listing; Nasdaq listing remains unchanged. Effective close of markets on March 16, 2026.
• Rationale: Cost savings from eliminating duplicate exchange fees; reduction in legal, accounting, and regulatory burdens; enhanced management focus on late‑stage development of NVG‑291.
• Shareholder Impact: No action required; Canadian shareholders retain full trading access on Nasdaq.
• Board Approval: Delisting approved by the Board of Directors; no shareholder vote needed per TSXV policy because shares remain listed on an acceptable market.
• Reporting Obligations: NervGen will continue as a reporting issuer under applicable securities laws in all Canadian provinces and territories.
• ATM Program Termination: The at‑the‑market equity program launched Dec 19, 2025 was terminated concurrent with the delisting.
• Shares issued: 245 common shares
• Weighted‑average price: $6.20 per share
• Net proceeds: $1,489 (aggregate)

Notable Quotes

• “The voluntary delisting reflects NervGen’s continued maturity and aligns with our evolution as we enter late‑stage development for NVG‑291,” said the Company in its release.